Microsurgery, stereotactic radiosurgery and endovascular treatment of sylvian fissure arteriovenous malformations: a systematic review
In brief
Microsurgery fully removed 8/8 and 94/94 sylvian AVMs in two cohorts
In separate surgical series, microsurgery completely removed all 8 and all 94 treated AVMs, and 40 of 41 in another cohort. A dedicated radiosurgery cohort reported 76% obliteration by 10 years, while no sylvian-specific curative embolization series was found. These selected, non-comparable reports support microsurgery for accessible lesions, but cannot establish which treatment is best.
- Journal
- Neurosurgical review (Q1)
- Published
- 14 November 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- A N Konovalov, S S Sergeeva, A A Artemyev, I A Erokhin, D A Starostenko, Yu V Pilipenko, et al.
- PMID
- 43026378
- DOI
- 10.1007/s10143-026-04579-1
Why clinicians should know about it
- Picked for Radiation Oncology (paper of the day, 15 November 2026): Systematic review compares stereotactic radiosurgery for cerebral AVMs
Abstract
Sylvian-fissure-region arteriovenous malformations (AVMs) are uncommon and anatomically heterogeneous; published labels often describe non-comparable lesions or populations. To update evidence for microsurgery, stereotactic radiosurgery (SRS), and endovascular treatment (EVT). Following PRISMA 2020, five databases were searched through May 2026 with citation chaining. Two reviewers independently screened records and extracted data. Dedicated sylvian/perisylvian cohorts were distinguished from broader cohorts and contextual technical reports. Incompatible endpoints, non-independent arms, and potentially overlapping cohorts were not pooled. Risk of bias and applicability were appraised. Nineteen reports were retained: 16 in the evidence synthesis and 3 as contextual background. Microsurgery achieved complete resection in 8/8, 40/41, and 94/94 patients. Transient deficits occurred in 4/8, 4/28, 9/94, and 18/41 patients; postoperative hematoma occurred in 2/94. Mortality windows varied. In the dedicated SRS cohort (n = 87), actuarial obliteration was 35% at 3 years, 60% at 4-5 years, and 76% at 10 years. Cumulative post-SRS hemorrhage was 5% at 1, 5, and 10 years (approximately 1% annually during latency); mortality was unreported. No dedicated curative EVT series for true sylvian AVMs was identified; available data described broader middle cerebral artery cohorts without sylvian-specific angiographic cure. Microsurgery is supported for carefully selected accessible sylvian-fissure AVMs, whereas SRS and embolization have complementary roles. Comparative superiority cannot be inferred. Future studies require explicit anatomical definitions, modality-specific denominators, angiographic endpoints, and standardized follow-up.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.